MTHFR - Thermolabile Variant, DNA Analysis
Order Name
MTHFR
Test Number: 1515625
Revision Date 10/22/2024
Test Number: 1515625
Revision Date 10/22/2024
| Test Name | Methodology | LOINC Code |
|---|---|---|
|
MTHFR Interpretation
|
Interpretive information. |
| SPECIMEN REQUIREMENTS | ||||
|---|---|---|---|---|
| Specimen | Specimen Volume (min) | Specimen Type | Specimen Container | Transport Environment |
| Preferred | 7mL (3mL) | Whole Blood | EDTA (Lavender Top) | Room Temperature |
| Alternate 1 | 7mL (3mL) | Whole Blood | ACD Solution A or B (Yellow Top) | Room Temperature |
| Alternate 2 | 2 Swabs | Buccal swab | Labcorp buccal swab kit | Room Temperature |
| Instructions | Specimen Requirements Specimen: Whole blood or LabCorp buccal swab kit (buccal swab collection kit contains instructions for use of a buccal swab) Volume: 7 mL whole blood or LabCorp buccal swab kit (Minimum Volume 3 mL whole blood or two buccal swabs) Container: Lavender-top (EDTA) tube, yellow-top (ACD) tube, or LabCorp buccal swab kit Storage Instructions: Maintain specimen at room temperature or refrigerate. Causes for Rejection: Frozen specimen; hemolysis; quantity not sufficient for analysis; improper container; one buccal swab; wet buccal swab. |
|||
| GENERAL INFORMATION | |
|---|---|
| Expected TAT | 6 - 10 days |
| Clinical Use | Methylenetetrahydrofolate Reductase (MTHFR) Thermolabile Variant, DNA Analysis Variants Analyzed: c.665C>T (p. Ala222Val), legacy name: C677T; and c.1286A>C (p. Glu429Ala), legacy name: A1298C. Results must be combined with clinical information for the most accurate interpretation. Molecular-based testing is highly accurate, but as in any laboratory test, diagnostic errors may occur. False positive or false negative results may occur for reasons that include genetic variants, blood transfusions, bone marrow transplantation, somatic or tissue-specific mosaicism, mislabeled samples, or erroneous representation of family relationships. This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration. |
| Notes | Hyperhomocysteinemia is multifactorial, involving genetic, clinical, and environmental risk factors. Reduced enzyme activity of methylenetetrahydrofolate reductase (MTHFR) is a genetic risk factor for hyperhomocysteinemia, particularly when serum folate levels are low. There are two common variants in the MTHFR gene that can decrease enzyme activity: c.665C>T (p. Ala222Val), legacy name C677T, and c.1286A>C (p. Glu429Ala), legacy name A1298C. These variants do not independently increase risk of conditions related to hyperhomocysteinemia in the absence of elevated homocysteine levels. Measurement of total plasma homocysteine is recommended. Patients should share their MTHFR genotype with physicians who are making decisions regarding chemotherapy treatments that depend on folate, such as methotrexate. Guidelines do not recommend genotyping of these two MTHFR variants in the evaluation of venous thromboembolism or obstetric risk due to limited evidence of clinical utility. Genetic coordinators are available for health care providers to discuss results and for information on how to order additional testing, if desired, at 1-800-345-GENE. |
| CPT Code(s) | 81291 |
| Internal Comments | PERMORMED IN HEMO OLD 83891; 83912; 83903x2; 83892x4; 83896x10; 83912-26 This is the old pre-auth form Click here for Molecular Pre-Authorization information. ----------------- 5/17/16 removed this from clin ifo The Methylenetetrahydrofolate Reductase (MTHFR) enzyme plays a major role in homocysteine metabolism and contains several known polymorphisms(C677T and A1298C). This mutation is reported to reduce MTHFR activity, resulting in hyperhomocysteinemia. This condition is a risk factor for cardiovascular disease, increased risk for arterial and venous thrombosis, and an increased risk for obstetrical complications. 7/11/17 updated schedule 8/7/19 added Refrigerated 8 Days, to stability - JK |
| Lab Section | Reference Lab |